Everolimus prevents coronary microvasculopathy in heart transplant recipients with normal coronary angiograms: an

F Tona1, M Fedrigo1, G Famoso1

  • 1Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.

Transplantation Proceedings
|September 23, 2014
PubMed

Insights

Everolimus may prevent coronary microvascular remodeling in heart transplant patients, preserving coronary flow reserve (CFR). This study found hypertrophic arterioles contribute to reduced CFR, with everolimus showing a protective effect.

Area of Science:

  • Cardiology
  • Transplantation Immunology
  • Vascular Biology

Background:

  • Coronary allograft vasculopathy (CAV) affects both epicardial and microvascular coronary arteries after heart transplantation (HT).
  • The impact of everolimus on coronary microvasculopathy in HT is not well understood.
  • This study investigates the pathological basis of impaired coronary flow reserve (CFR) and everolimus's effect on microvascular remodeling.

Purpose of the Study:

  • To assess the pathological substrate of coronary flow reserve (CFR) impairment in heart transplant (HT) patients.
  • To evaluate the effect of everolimus on microvascular remodeling and CFR in HT recipients.

Main Methods:

  • Studied 28 HT patients with normal coronary angiograms, divided by immunosuppression (cyclosporine + everolimus vs. cyclosporine + mycophenolate mophetil).
  • Assessed microvascular remodeling and fibrosis using digital microscopy.
  • Measured coronary flow velocity and calculated CFR using transthoracic Doppler echocardiography during adenosine infusion.

Main Results:

  • Reduced CFR (≤2.5) correlated with increased arteriolar wall thickness and microvascular remodeling.
  • Everolimus therapy was associated with significantly lower arteriolar wall thickness (15±2 vs. 32±4 μm) and higher CFR (3.2±0.5 vs. 2.8±0.9).
  • Capillary density and fibrosis were similar between groups.

Conclusions:

  • Hypertrophic remodeling of coronary arterioles is the pathological basis for reduced CFR in HT patients.
  • Everolimus may prevent microvascular remodeling in HT recipients.
  • Everolimus appears to preserve coronary flow reserve in heart transplant patients.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
887
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
815
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.6K
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
45
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
24